Maternal asthma, asthma medication use, and the risk of congenital heart defects

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 2, 2009, Pages 161-168

  Lin, Shao ^a   Herdt Losavio, Michele ^a   Gensburg, Lenore ^b   Marshall, Elizabeth ^c   Druschel, Charlotte ^a  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b UNIVERSITY AT ALBANY   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Asthma; Heart defects; Medication

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; CORTISONE; DECONGESTIVE AGENT; EPHEDRINE; ORCIPRENALINE; PREDNISONE; SALBUTAMOL; STEROID; TERBUTALINE; THEOPHYLLINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BIRTH; BIRTH CERTIFICATE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INFANT; INTERVIEW; LIVE BIRTH; MAJOR CLINICAL STUDY; MALE; MATERNAL DISEASE; POPULATION BASED CASE CONTROL STUDY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; REGISTER; RISK ASSESSMENT; TELEPHONE; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RISK; YOUNG ADULT;

EID: 62949092201     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20523     Document Type: Article

References (20)

1. Agency for Toxic Substances and Disease Registry. 2004. Maternal exposure to volatile organic compounds and the risk of congenital heart defects. Springfield, Virginia: National Technical Information Service; Publication number PB2004-102339.
2. Danielsson BR, Skold A-C, Johansson A, et al. 2003. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 193:168-176.
3. GlaxoSmithKline. 2001. Product Information: Ventolin (albuterol, USP) Inhalation Aerosol. GlaxoSmithKline RL-963.
4. Jadad AR, Sigouin C, Mohide PT, et al. 2000. Risk of congenital malformations associated with treatment of asthma during early pregnancy. Lancet 355:119.
5. Kallen B, Olausson PO. 2007. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 63:383-388.
6. Kallen B, Rydhstroem H, Aberg A. 1999. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 93:392-395.
7. Kirby ML. 2007. Cardiac development. New York: Oxford University Press.
8. Mabie WC. 1996. Asthma in pregnancy. Clin Obstet Gynecol 39:56-69.
9. Namazy JA, Schatz M. 2004. Update in the treatment of asthma during pregnancy. Clin Rev Allergy Immunol 26:139-148.
10. National Asthma Education and Prevention Program. 1993. Publication No. 93-3279A. Bethesda, MD: National Heart, Lung, and Blood Institute.
11. National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. 2005. NAEPP Expert Panel Report. Managing asthma during pregnancy: Recommendations for pharmacologic treatment - 2004 update. J Allergy Clin Immunol 115:34-46.
12. New York State Department of Health. 2007. Congenital Malformations Registry Summary Report. New York State Department of Health. Osur SL. 2005. The management of asthma and rhinitis during pregnancy. J Women Health 14:263-276.
13. Park JM, Schmer V, Myers TL. 1990. Cardiovascular anomalies associated with prenatal exposure to theophylline. South Med J 83:1487-1488.
14. Perlow JH, Montgomery D, Morgan MA, et al. 1992. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 167:963-967.
15. Romano-Zelekha O, Hirsh R, Blieden L, et al. 2001. The risk for congenital heart defects in offspring of individuals with congenital heart defects. Clin Genet 59:325-329.
16. Rosa F. 1999. Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol 103:S360-S361.
17. Sadler TW. 2000. Susceptible periods during embryogenesis of the heart and endocrine glands. Environ Health Perspect 108:555-561.
18. th ed. Philadelphia: Lippincott Williams and Wilkins. p 271.
19. Sakabe M, Matsui H, Sakata H, et al. 2005. Understanding heart development and congenital heart defects through developmental biology: A segmental approach. Congen Anom 45:107-118.
20. Schatz M, Zeiger RS, Harden K, et al. 1997. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 100:301-306.